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Background: Previous studies have demonstrated that claudin-6 functions as a cancer suppressor in human MCF-7
breast cancer cells. The growth inhibitory effect could be attributed to inhibition of cell proliferation and induction
of apoptosis. The purpose of the current study was to examine the involvement of apoptosis signal-regulating
kinase 1 (ASK1) in the anticancer effect of claudin-6.
Methods: Immunohistochemical analysis was performed to evaluate the ASK1 protein expression and the
correlation between ASK1, claudin-6 and clinicopathological features in 85 samples of breast invasive ductal
carcinomas (IDC). Western blotting and RT-PCR was carried out to examine the expression of ASK1 and claudin-6 in
MCF-7 cell clones transfected with claudin-6.
Results: Immunohistochemical analysis showed that ASK1 expression was significantly related with that of
claudin-6 in breast invasive ductal carcinomas (P < 0.05). In addition, a positive correlation between ASK1 and
C-erb B 2 protein expression was identified (P < 0.05). Western blotting and RT-PCR consistently revealed that the
level of ASK1 protein and mRNA was upregulated in MCF-7 cell clones transfected with claudin-6.
Conclusions: Our data suggests, for the first time, that the ASK1 signal may play a positive role in the inhibitory
effect of claudin-6 in breast cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1200314318763661
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Breast cancer is one of the most frequent and deadly
cancers in women [1]. Emerging evidence points toward
a pivotal role of tight junction (TJ) in mediating tumori-
genic growth of breast cancer [2,3]. TJs are junctional
complexes which mediate cell-to-cell adhesion in epithe-
lial and endothelial cellular sheets [4], and which affect
cell polarity and tight junction formation [5].
Claudins (CLDNs) constitute a family of integral mem-
brane proteins and have been identified as prominent
structural components of TJ strands [5,6]. The CLDNs
which include 27 members at least [7], encode 20-27
kDa proteins with four transmembrane domains and* Correspondence: clondy_123@163.com
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reproduction in any medium, provided the ortwo extracellular loops [8]. The expression of CLDNs is
often different in various types of human tumor [9,10].
Many studies have demonstrated that claudins may par-
ticipate in several signal transduction pathways [11-15].
For instance, inhibition of c-jun NH2-terinal kinase
(JNK) and p38 mitogen-activated protein kinase (p38
MAPK) selectively modulates the expression of claudin-
4, -8 and −9 to enhance TJ barrier function in mammary
epithelial cells [16], And p38 MAPK activity is involved
in the epithelial barrier dysfunction in which claudin-7
protein plays a major role [17]. It is well known that
apoptosis signal-regulating kinase 1 (ASK1) phosphory-
lates and actives both p38 and JNK pathway [18]. ASK1
is a member of the MAPKKK family and functions as a
promoting apoptosis gene in response to common pro-
apoptosis stresses [19]. However, there is little. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological features and the expression
of ASK1 in 85 IDC samples
Clinicopathological
features
Cases ASK1 expression (n) χ2 P
Positive Negative
Age (years) 0.017 0.896
≥45 58 18 40
<45 27 8 19
Histological grade 0.668 0.414
I ~ II 21 8 13
III 63 18 45
Tumor size 0.21 0.646
≥5 cm3 66 21 45
<5 cm3 19 5 14
Lymph node metastasis 0.527 0.468
Positive 41 11 30
Negative 44 15 29
TNM stage 0.336 0.562
I,II 55 18 37
III,IV 30 8 22
Lesion location 2.406 0.121
Right 45 10 35
Left 34 13 21
ER 0.105 0.746
Positive 37 12 25
Negative 48 14 34
PR 0.425 0.515
Positive 38 13 25
Negative 47 13 34
C-erb B-2 5.747 0.017
Positive 27 13 14
Negative 58 13 45
Statistical analyzed by Pearson’s chi-square test.
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especially claudin-6.
In our previous study, we found that claudin-6 is pre-
ferentially expressed in mammary epithelial cells and
functions as a potential breast cancer suppressor
gene [20], which is supported by the follow-up study of
Osanai [21]. Recently, we have discovered that the low
level expression of claudin-6 gene contributed to malig-
nant progression of breast cancer [22]. A previous study
has described that breast cancer tissues also expressed
lower levels of ASK1 compared with normal mammary
tissues [23]. Therefore, the purpose of the current study
is to discover the relationship between ASK1 and
claudin-6 in breast cancer and to explore the pathways
involves the activation of ASK1.
Methods
Patients and tissue samples
The breast samples were obtained from 2006–2010 in
the Jilin Oil Field General Hospital in Songyuan, Jilin
province, China. A total of 85 breast invasive ductal car-
cinomas (IDC) aged 26 to 77 with a mean age of 51 were
included in this study. The study was approved by the
Ethics Committee of Jilin University. Clinicopathological
features of 85 IDC samples are summarized in Table 1.
Cell culture
Human breast cancer cell line MCF-7 cell clones expres-
sing an vector pcDNA3.1 (+) or claudin-6 were cultured
as previously described [22].
Quantitative RT-PCR
Total RNA was extracted from clone cells using TRIzol
(Invitrogen, USA) following the manufacturer’s instruc-
tions. One microgram of total RNA was subjected to
reverse transcription to synthesize cDNA using the M-
MuLV reverse transcriptase (TaKaRa, Japan) at 42°C for
1 hour, and 0.5 ug cDNA was used for PCR. ASK1 and
claudin-6 were amplified along with GAPDH as an en-
dogenous control following the instructions of Premix
LA Taq Kit (TaKaRa, Japan). The PCR reaction condi-
tions and the primer sequences of ASK1, claudin-6 and
GAPDH are shown in Table 2. After electrophoresis,
the gel was captured and analyzed by the image system
(Syngene, Cambridge, UK).
Western blotting analysis
The Western blotting analyses were performed as
described previously [22]. Primary antibodies included
ASK1 (rabbit polyclonal antibody, 1:1000, Bioworlde
Technology), claudin-6 (rabbit polyclonal antibody,
1:1000, Bioworlde Technology) and β-actin (mouse poly-
clonal antibody, 1:1000, Santa Cruz). Secondary anti-
bodies for the detection: anti-rabbit IgG (1:2000,Proteintech Group) and anti-mouse IgG (1:2000, Pro-
teintech Group).
Immunohistochemistry
Immunohistochemical staining was carried out as
described in our previouspublications [24]. The primary
antibodies against ASK1 (rabbit polyclonal antibody,
1:200, Bioworlde Technology) and claudin-6 (rabbit
polyclonal antibody, 1:200, Bioworlde Technology) were
used. The negative controls were handled in the same
way except PBS instead of primary antibody.
Positive-staining exhibits brown staining, Claudin-6
was shown on the cell membrane and/or cytoplasm in
breast cancer tissues [24], and ASK1 expressed on the
breast cancer cytoplasm according to the manufacturer’s
Instructions of ASK1 antibody. Immunostaining was
Table 2 Primers used for PCR
Gene Sequence of primers Size of PCR(bp) Denaturation temperature (°C) Cycles
ASK1 sense 5’-TTCACACAAAACGGATGTAACATT-3’ 198 56 30
antisense 5’-CCTAAACAGTTATGGTCACATTTTGG-3’
Claudin-6 sense 5’-TTCATCGGCAACAGCATCGT-3’ 345 58 35
antisense 5’-GGTTATAGAAGTCCCGGATGA-3’
GAPDH sense 5’-TGTTGCCATCAATGACCCCTT-3’ 202 56 25
antisense 5’-CTCCACGACGTACTCAGCG-3’
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tion, and positive cells, negative cells and total cells of
five different visual fields were numbered in each speci-
men. Scoring was performed as follows: negative (−),
<10% positive tumor cells; positive (+), ≥10% positive
tumor cells.
Statistical analyses
All computations were carried out using the software of
SPSS version 19.0 for Windows (SPSS Inc, IL, USA).
Chi-Square test was used to examine categorical data.
Unpaired t-tests were performed to evaluated data of
target mRNA and protein. The data are presented as
means ± standard deviation (SD) from at least three in-
dependent experiments. P < 0.05 was considered statisti-
cally significant.
Results
Association of ASK1 expression with the
clinicopathological features of breast invasive ductal
carcinomas
The clinicopathological characteristics of the patients
are summarized in Table 1. In order to investigate
whether ASK1 protein expression was associated with
clinicopathological features of patients of breast cancer,
we correlated immunohistochemical ASK1 staining
results with clinicopathological features. In this study,
ASK1 protein was evaluated in the cytoplasm of breast
cancer (Figure 1A), and the positive expression of
ASK1 protein was found in 30.59% (26/85) of breast
IDCs. ASK1 protein expression had no correlation withFigure 1 Expression and location of ASK1 in breast invasive ductal ca
staining was predominant in the cytoplasm of breast carcinoma tissues. (B)age (P = 0.896), histological grade (P = 0.414), tumor
size (P = 0.646), lymph node metastasis (P = 0.468),
TNM stage (P = 0.562) and lesion location (P = 0.121).
But interestingly, we found that ASK1 had relationship
with C-erb B 2 protein expression (P = 0.017).
Correlation between the expression of ASK1 and claudin-
6 in breast cancer tissues
We have found that the expression of claudin-6 was
reduced in breast invasive ductal carcinomas [24]. The
expression of claudin-6 (Figure 1A, 1B) and ASK1
(Figure 2A, 2B) was examined by immunohistochemis-
try, and the correlation between claudin-6 and ASK1
was analyzed by Pearson’s chi-square test. As shown in
Table 3, the positive expression rate of claudin-6 was
27.09% (23/85) in IDC specimens, and cells were posi-
tive for ASK1 in 30.59% (26/85) of IDC cases. Half
(13/26) of the ASK1 positive cases were positively stain-
ing for claudin-6, but only 16.95% (10/59) of ASK1 nega-
tive cases stained positively for claudin-6. Statistical
analysis revealed that claudin-6 expression was positive
correlated with ASK1 expression in breast invasive
ductal carcinomas (P = 0.0016).
Correlation between the expression of claudin-6 and
ASK1 in breast cancer cells
We found the correlation between claudin-6 and ASK1
expression in breast invasive ductal carcinomas tissues,
but their relationship in breast cancer cell line was un-
known. We used MCF-7 cells transfected with
pcDNA3.1 (+) and three G418 resistant MCF-7 clones,rcinoma (IDC) (Original magnification × 400). (A) ASK1 positive
ASK1 negative staining was seen in IDC tissues.
Figure 2 Expression and location of claudin-6 in breast invasive ductal carcinoma (IDC) (Original magnification × 400). (A) Claudin-6 was
expressed in the membrane and cytoplasm of IDC tissues. (B) Claudin-6 was weakly expressed in IDC tissues.
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upregulated, ASK1 had a higher expression level
than that in empty vector group (Figure 3A, 3C). Quan-
titative RT-PCR and western blot analysis showed that
the level of claudin-6 mRNA and protein positively cor-
related with the level of ASK1 mRNA and protein
(Figure 3B, 3D).
Discussion
In the previous study, We found that the expression
level of claudin-6 was lower in two human breast cancer
cells (MCF-7 and BT474) and one breast cancer sample
than that in normal breast tissues [20]. In addition, we
also discovered the growth, migration and invasion of
MCF-7 cells were inhibited by overexpression of
claudin-6 [22]. One report has shown that the expression
of ASK1 is lower in breast cancer tissues than that in
normal tissues [23]. As we all known, ASK1 is regulated
in response to various cellular stresses, including cell sur-
vival, proliferation, differentiation, and so forth. There-
fore, in the current study, we attempted to elucidate the
relationship between the expression of claudin-6 and
ASK1 using clinicopathological features and classical
prognostic factors in breast pathology, including the ex-
pression of immunohistochemical markers of prognostic
significance (ER, PR, C-erb B 2) (Table 1). To the best of
our knowledge, this is the first study to demonstrate an
association between the protein expression of claudin-6
and ASK1 in a large series of breast invasive ductal car-
cinomas and the breast cancer cells.
We have previously found that the expression of
claudin-6 was negatively correlated with lymphaticTable 3 The correlation between the expression of claudin-6
ASK1 expression Cases (n,%) Claudi
Positive
Positive 26 (30.59%) 13 (50%)
Negative 59 (69.41%) 10 (16.95%)
Case (n) 85 (100%) 23 (27.09%)
Statistical analyzed by Pearson’s chi-square test.metastasis of breast IDCs [24], but we did not found the
correlation between ASK1 expression and the lymphatic
metastasis (Table 1). This may be mainly due to that the
ASK1 signal pathway is not the only pathway to be regu-
lated by claudin-6. Besides that, we found the correlation
of claudin-6 and ERα (p = 0.033), and also discovered
that ERα regulated claudin-6 in MCF-7 cells [25]. We
failed to find the correlation between ASK1 and ER. And
the reason high likely is the cross-talk among different
signaling pathways, as we discussed in the case of failing
to discover the correlation of ASK1 and lymphatic me-
tastasis. However, we revealed the correlation between
ASK1 and C-erb B 2 (Table 1). These results indicate the
role of C-erb B 2 in ASK1 signal pathway. We next ana-
lyzed the relationship of C-erb B 2 and claudin-6, but we
found no relationship between them (data not shown).
Therefore, these data suggest that the inhibitory effect of
claudin-6 in breast cancer mainly results from the regu-
lation of ASK1.
Besides analysis of the breast cancer tissues, we also
analyzed the correlation of ASK1 and claudin-6 mRNA
and protein in breast cancer cell lines. We have found
claudin-6 was a anti-cancer gene in claudins family [22],
and the up-regulation of claudin-6 has important clinical
implication, but details of the mechanism was not clear.
C-jun NH2-terinal kinase (JNK) and p38 mitogen-
activated protein kinase (p38 MAPK) signal pathway
played a positive role in the process of claudin-4, -8 and
−9 enhancing TJ barrier function in mammary epithelial
cells [16]. ASK1 actives JNK and p38 pathway and
induces apoptosis in various cells through mitochondria-
dependent caspase activation [18,26-28]. ASK1and ASK1 in breast invasive ductal carcinomas
n-6 expression (n,%) χ2 P
Negative
13 (50%) 9.988 0.0016
49 (83.05%)
72 (72.01%)
Figure 3 Correlation of claudin-6 and ASK1 in breast cancer cells. Line 1 is empty vector group; lines 2, 3 and 4 are three clone groups.
(A) (B) RT-PCR assay examined the mRNA levels of claudin-6 and ASK1. (C) (D) Western blot assay detected claudin-6 and ASK1 protein expression.
*,**P<0.05, vs. vector group. Results are means ± standard deviation for three independent experiments.
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receptor-associated factors2/6 [29], DAXX [30], TRADD
[31], RIP1 [32], and FADD [33]. And several cellular
proteins, for example, thioredoxin [26], Hsp90 [34] and
14-3-3 [35] were also reported to interact with ASK1
and inhibit ASK1 activity. Here, we demonstrated that
ASK1 was upregulated when claudin-6 gene was trans-
fected into MCF-7 cells (Figure 3). Therefore, the
present study indicates that ASK1 signal participates in
the pro-apoptosis function of claudin-6.Conclusions
As a conclusion, our study suggests that the ASK1 ex-
pression is low in breast cancer, and the levels of ASK1
mRNA and protein expression are correlated with that
of claudin-6. We have identified a novel mechanism re-
sponsible for the pro-apoptosis function of claudin-6,
and ASK1 may become a target for breast cancer treat-
ments. However, we still need further study to clarify the
detail of this mechanism.Competing interests
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